Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Company · Belgium
Declared costs: €1M+ a year · in the register since 2014
NGO · Germany
Declared costs: not declared · in the register since 2008
Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislation · Medicinal products for human use · Revision of the EU legislation on medicines for children and rare diseases
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Deutsche Sozialversicherung Europavertretung · filed 2 Oct 2025 · source
Targeted legislative adjustments can be useful in achieving the objectives of the MDR and IVDR, also in view of the considerable difficulties manufacturers and notified bodies faced during the transition from the previous legal framework.
AbbVie · filed 3 Aug 2026 · source
AbbVie welcomes the Commissions targeted revision of the MDR/IVDR and appreciates the intent to update Regulation (EU) 2017/745 based on practical experience and broadly supports many of the Commissions proposals. These proposals introduce important measures to support innovation and improve regulatory efficiency, however, there is room for further improvement on several aspects.
AbbVie · filed 27 Apr 2021 · source
As a research-driven biopharmaceutical company, AbbVie supports the Commission objectives to create a patient-centered and globally competitive European pharmaceutical policy environment that enhances the availability of medicines across the EU and incentivizes development of treatments for unmet health needs in both diseases where no treatments exist as well as those where the existing treatments do not…
Deutsche Sozialversicherung Europavertretung · filed 27 Apr 2021 · source
Health systems in the EU face the challenge of ensuring a high quality of affordable supply of medicines in the face of high prices. The German Social Insurance Agency therefore welcomes the EU’s intention to revise European pharmaceutical legislation.
Filed in German · English published by the European Commission
Deutsche Sozialversicherung Europavertretung · filed 2 Nov 2023 · source
The German Social Insurance Board (DSV) welcomes the Commission’s objectives of the reform proposals. They provide an opportunity to ensure equal access to medicines for patients in all Member States and to strengthen the security of supply of medicines as well as the adequacy of existing incentive schemes for drug development.
Filed in German · English published by the European Commission
Deutsche Sozialversicherung Europavertretung · filed 4 Jan 2021 · source
The German social security umbrella organisations in Germany welcome the plan to revise the existing incentive schemes for orphan medicinal products and paediatric medicinal products and agrees with the European Commission that the aim of this revision must be to: (1) focus support on areas where the regulations have not shown the desired success; (2) end support for areas where it is not necessary; (3) link funding…
Filed in German · English published by the European Commission
AbbVie · filed 6 Jan 2021 · source
As an innovative biopharmaceutical company with over 11.000 employees in the EU, AbbVie supports the Commission’s aims to develop more medicines for unmet needs, speed access to new therapies for all EU citizens, and ensure the maximum benefits from scientific and technological advances.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.